With approval, the HeartMate 3 System offers physicians in Europe the most advanced ventricular assist technology available to support the management of patients with advanced stage heart failure ST.

MOMENTUM 3 Study meets primary endpoint for short-term indication Results presented during late-breaking clinical trial session at the AHA Scientific Sessions MOMENTUM 3 Study data published in the ...

A six-month analysis of the pivotal MOMENTUM 3 trial found that patients implanted with the new HeartMate 3 left ventricular assist system (LVAS) had fewer adverse clotting and bleeding events than ...

New data from the ARIES trial show for the first time that an aspirin-free regimen can improve outcomes for people living with the heart pump by reducing hospitalizations without increasing the risk ...

Pump thrombosis has been such a well-established shortcoming of left ventricular assist devices (LVADs), that one heart surgeon went so far as to borrow Winston Churchill's phraseology to describe it ...

New data from the MOMENTUM 3 study showed for the first time that a heart pump can extend survival to five years and beyond for advanced heart failure patients Prior data1 have shown survival for ...

If headlines about Abbott’s HeartMate 3 problems are giving you déjà vu, you’re not alone. With three recalls related to the left ventricular assist device (LVAD) so far this year, the news is ...